Trial Profile

A Phase 1 Study to Assess Safety and Tolerability of Odronextamab (REGN1979) an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, and Cemiplimab (REGN2810), an Anti-Programmed Death-1 Monoclonal Antibody in Patients With B-Cell Malignancies (CLIO-1)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; Odronextamab (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions
Acronyms CLIO-1
Sponsors Regeneron Pharmaceuticals

02 Feb 2026 Planned End Date changed from 27 Dec 2025 to 31 May 2026.
02 Feb 2026 Planned primary completion date changed from 27 Dec 2025 to 31 May 2026.
08 Aug 2025 Planned End Date changed from 25 Dec 2026 to 27 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com